No hostile to hostile

The French pharma group is taking its rebuffed $69ashare offer directly to the U.S. biotech’s shareholders. This shows Sanofi’s confidence that it can clinch a deal, and worry that waiting will make its target more expensive. But a sweeter offer is still more than likely.